The lancet. Diabetes & endocrinology
-
Lancet Diabetes Endocrinol · Dec 2015
Randomized Controlled Trial Multicenter StudyMyostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.
Myostatin inhibits skeletal muscle growth. The humanised monoclonal antibody LY2495655 (LY) binds and neutralises myostatin. We aimed to test whether LY increases appendicular lean body mass (aLBM) and improves physical performance in older individuals who have had recent falls and low muscle strength and power. ⋯ Eli Lilly and Company.
-
Lancet Diabetes Endocrinol · Dec 2015
Randomized Controlled Trial Clinical Trial2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
An artificial pancreas (AP) that can be worn at home from dinner to waking up in the morning might be safe and efficient for first routine use in patients with type 1 diabetes. We assessed the effect on glucose control with use of an AP during the evening and night plus patient-managed sensor-augmented pump therapy (SAP) during the day, versus 24 h use of patient-managed SAP only, in free-living conditions. ⋯ European Commission.